SCHEMBL23601440

SCHEMBL23601440

CN(c1cccc(-c2cnc(C3CC3)cn2)c1)c1nc2nncn2c2cc(Cl)ccc12

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
CYP11B1 P15538 1/20 0.34
TNF P01375 1/20 0.34
MAT2A P31153 1/20 0.33
HRH4 Q9H3N8 3/20 0.32
TP53 P04637 2/20 0.32
MAPT P10636 2/20 0.32
POLB P06746 1/20 0.31
CSNK2A2 P19784 1/20 0.30
CSNK2B P67870 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31169400 1.00 FNTA (0.34) FNTAFNTBCYP11B1TNFMAT2A
SCHEMBL31229439 0.90 FNTA (0.34) FNTAFNTBCYP11B1MAT2AHRH4
SCHEMBL23577377 0.90 FNTA (0.34) FNTAFNTBCYP11B1MAT2AHRH4
SCHEMBL23577357 0.90 FNTA (0.35) FNTAFNTBCYP11B1MAT2AHRH4
SCHEMBL23601645 0.90 FNTA (0.36) FNTAFNTBMAT2AHRH4TP53
SCHEMBL23576819 0.89 KDM1A (0.36) FNTAFNTBCYP11B1MAT2AHRH4
SCHEMBL23601450 0.88 CYP11B1 (0.33) FNTAFNTBCYP11B1MAT2AHRH4
SCHEMBL23601336 0.88 TNF (0.33) TNFMAT2A
SCHEMBL23577374 0.86 MAT2A (0.33) CYP11B1MAT2ACSNK2A2CSNK2B
SCHEMBL30961076 0.86 MAT2A (0.33) CYP11B1MAT2ACSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885CYP11B1 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.